Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Cancers 2010, 2(4), 2044-2054; doi:10.3390/cancers2042044
Review

Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions

*  and
Received: 22 October 2010; in revised form: 29 November 2010 / Accepted: 30 November 2010 / Published: 2 December 2010
(This article belongs to the Special Issue Pancreatic Cancer)
View Full-Text   |   Download PDF [141 KB, updated 3 December 2010; original version uploaded 2 December 2010]   |   Browse Figures
Abstract: Pancreatic cancer is one of the most lethal cancers, where curative surgical resections are rare and less than 5% of patients experience long-term survival. Despite numerous clinical trials, improvements in the systemic treatment of this disease have been limited. Gemcitabine, a nucleoside analogue, is still considered the standard of care chemotherapy for most patients in the advanced disease setting. To exert its cytotoxic effects, gemcitabine must enter cells via nucleoside transporters, most notably human equilibrative nucleoside transporter 1 (hENT1). Increasingly strong evidence suggests hENT1 is a prognostic biomarker in gemcitabine-treated pancreatic cancer, and may well be a predictive biomarker of gemcitabine efficacy. In this review, we synthesize the literature surrounding hENT1 in pancreatic cancer, identify the key outstanding questions, and suggest strategies to prospectively evaluate the clinical utility of hENT1 in future clinical studies.
Keywords: nucleoside transporters; hENT1; pancreatic adenocarcinoma; predictive tool; individualized medicine nucleoside transporters; hENT1; pancreatic adenocarcinoma; predictive tool; individualized medicine
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Spratlin, J.L.; Mackey, J.R. Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions. Cancers 2010, 2, 2044-2054.

AMA Style

Spratlin JL, Mackey JR. Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions. Cancers. 2010; 2(4):2044-2054.

Chicago/Turabian Style

Spratlin, Jennifer L.; Mackey, John R. 2010. "Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions." Cancers 2, no. 4: 2044-2054.



Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert